One of India’s comparative advantages is its Pharmaceutical Industry. Given low production and labour costs as well as an ageing global population, increasing awareness (ongoing and heightened by COVID-19) and improving accessibility and affordability, it is expected that India’s Pharma companies will benefit. It’s not without its challenges, but with increasing R&D spending and a growing local market, they will attract greater foreign and local investment. Read our article (5-7 minutes) on the current status and our thoughts on how it could play out. We also highlight the Pharma companies we currently hold in India Avenue portfolio.
Where to from here for India?Next
Indian pharma could stand to capitalise on post-virus markets: Siva
India Avenue’s exposure to the Adani Group
January 30, 2023 April 30, 2023
India Avenue Equity Fund – 12 months of underperformance
December 30, 2022 April 30, 2023
India’s digital transformation to drive growth
September 30, 2022 April 30, 2023
India’s road to economic prominence
September 30, 2022 April 30, 2023
India Avenue is a boutique investment management firm providing investment solutions that allow our clients to benefit from India’s remarkable growth story.
The journey towards the “birth” of India Avenue originated in 2005, when ING Investment Management started a business in India as a separate division, utilising a practiced multi-manager philosophy in markets like Australia, and exported it to India. Three of our founders, Mugunthan Siva, Rajeev Thakkar and Sajjan Raut Desai worked together for INGIM (India), building investment strategies and structures, under this philosophy and applying them to Indian capital markets
In 2011 our founders started discussing the possibility of building an investment firm with a capability to provide a focus on India as an stand-alone investment jurisdiction for foreign investors. The founders identified Australia and New Zealand as nascent markets for investing in regional locations, with the potential to accelerate given education and insights which the firm could provide.
By 2015 the group of founders decided to work full-time on this concept to bring it to life. They did this by leaving their existing employment, thus exercising high conviction in the investment region of India as a long-term structural story for investors in Australia and New Zealand. Thus, the firm India Avenue Investment Management was registered and came to life in 2015 in Sydney, Australia.
After building our business for a period of 12 months, our first fund, The India Avenue Equity Fund was launched on 6th September 2016, with strong service provider partners like Equity Trustees (RE), Mainstream (Fund Administrator), KPMG (Fund Auditor) and BNP India (Custodian).
India Avenue is now a boutique investment business firm, with clients spread across family offices, high net worth individuals, wealth advisers and financial planning firms. Our firm has focused on education and knowledge as a driver of investment behaviour and have taken a long-term approach towards Australian and New Zealand investors contemplating an allocation to India’s growth as part of their portfolios. Our firm has assets in excess of A$50m and the India Avenue Equity Fund is rated “Recommended”* by Lonsec and is available on multiple investment platforms across Australia and New Zealand.